MDACC Study No:2006-0816 ( NCT No: NCT00861406)
Title:An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients with Resected Stage II and III (N1a, N2a) Melanoma
Principal Investigator:Wen-Jen Hwu
Treatment Agent:gp100 peptide; Peg Intron
Study Status:Closed
Study Description:The goal of this clinical research study is to find the best dosing schedule of
a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a
peptide vaccine (gp100) that may help improve immune response in patients that
had Stage II or Stage III melanoma and are free of the disease. The safety and
tolerability of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:gp100 peptide
Peg Intron
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Merck
Return Visit:Every 3 weeks
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wen-Jen Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults